Avalide
NDC Package 54868-5465-0

11-digit billing NDC: 54868546500

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Avalide is ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension.AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy.AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks.Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Marketed by Physicians Total Care, Inc., this product is identified by NDC 54868-5465 and is authorized under FDA application NDA020758.

Identification & Billing

NDC Package Code
54868-5465-0
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
54868546500
RxNorm Crosswalk
  • RxCUI: 310792 - irbesartan 150 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet
  • RxCUI: 310792 - hydrochlorothiazide 12.5 MG / irbesartan 150 MG Oral Tablet
  • RxCUI: 310792 - HCTZ 12.5 MG / irbesartan 150 MG Oral Tablet
  • RxCUI: 310793 - irbesartan 300 MG / hydroCHLOROthiazide 12.5 MG Oral Tablet
  • RxCUI: 310793 - hydrochlorothiazide 12.5 MG / irbesartan 300 MG Oral Tablet

Clinical Specifications

Proprietary Name
Avalide
Dosage Form
-
Usage Information
AVALIDE® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension.AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy.AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks.Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy.Data from Studies V and VI [see Clinical Studies(14.2)] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b.Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)*Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)*Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)*Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)*  *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis).The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone).The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic).

Regulatory & Marketing

Labeler Name
Physicians Total Care, Inc.
FDA Application #
NDA020758
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
11-01-2005
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (54868-5465). Click a package code to view its specific billing and regulatory data.

90 TABLET, FILM COATED in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 54868-5465-0 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Avalide, labeled by Physicians Total Care, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Physicians Total Care, Inc. on November 01, 2005. The current certification is valid through December 31, 2017.

How is this Physicians Total Care, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 54868546500. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
54868-5465-0
11-Digit CMS (5-4-2)
54868-5465-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.